Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer

  • Athenex Inc (NASDAQ:ATNX) announced a clinical trial collaboration and supply agreement with Merck Co & Inc (NYSE:MRK). 
  • The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex's oral paclitaxel combined with Merck's Keytruda (pembrolizumab) for certain NSCLC patients.
  • The agreement will support the trial's expansion phase to investigate further the preliminary results of the KX-ORAX-011 Phase 1 trial evaluating Oraxol (encequidar plus oral paclitaxel) in combination with pembrolizumab for certain NSCLC patients. 
  • The two companies will form a Joint Development Committee to review the clinical trial results.
  • The NSCLC expansion cohort is actively recruiting and aims to enroll approximately 50 patients.
  • Price Action: ATNX shares are up 2.15% at $0.48 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.